งานวิจัยเบต้ากลูแคน

Placebo-driven clinical trials of yeast-derived β-(1,3) glucan in children with chronic respiratory problems

Views

Placebo-driven clinical trials of yeast-derived β-(1,3) glucan in children with chronic respiratory problems

Vaclav Vetvicka1, Josef Richter2, Vladimir Svozil3, Lucie Rajnohová Dobiášová2, Vlastimil Král2

1University of Louisville, Department of Pathology, Louisville, KY, USA; 2Zdravotní ústav se sídlem v Ústí nad Labem, Czech Republic; 3Sanatorium EDEL, Zlaté Hory, Czech Republic

All authors contributed equally.

Corresponding to: Dr. Vaclav Vetvicka. University of Louisville, Department of Pathology, 511 S. Floyd, Louisville, KY 40202, USA. Email: vaclav.vetvicka@louisville.edu.

Background: The role of glucan in stimulation of immune reactions has been studied for several decades. In this report we focused on the effects of orally administered glucan in children with chronic respiratory problems.

Materials and methods: We measured the levels of albumin, lysozyme and CRP in saliva of 40 children aged 8-12 years and evaluate the effects of 100 mg/d oral dose of glucan.

Results: We found a significant increase in production of changes in production of lysozyme and CRP in glucan-treated children. In addition, a strong improvement in general conditions was found.

Conclusions: Short-term oral application of natural immunomodulator β-glucan stimulated mucosal immunity of children with chronic respiratory problems.

Keywords: Glucan; children; mucosal immunity; lysozyme; saliva


Submitted Jun 08, 2013. Accepted for publication Jul 01, 2013.

doi: 10.3978/j.issn.2305-5839.2013.07.01